The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 101-59-87
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Omelyanovskiy V.V.

Center for Expertise and Quality Control of Medical Care;
Russian Medical Academy of Continuous Professional Education;
Research Financial Institute;
Semashko National Research Institute of Public Health

Bezdenezhnykh T.P.

Center for Expertise and Quality Control of Medical Care;
Financial Research Institute

Teptsova T.S.

Center for Expertise and Quality Control of Medical Care;
I.M. Sechenov First Moscow State Medical University (Sechenov University)

Musina N.Z.

Center for Expertise and Quality Control of Medical Care;
St. Petersburg State Chemical Pharmaceutical University;
Russian Presidential Academy of National Economy and Public Administration

Foreign experience in economic assessment and financing of CAR-T therapy: prospects for Russia

Authors:

Omelyanovskiy V.V., Bezdenezhnykh T.P., Teptsova T.S., Musina N.Z.

More about the authors

Journal: Medical Technologies. Assessment and Choice. 2020;(3): 17‑28

DOI: 10.17116/medtech20204103117

Views: 3932

Downloaded: 74

Download PDF (RU)
Contact the author
Table of contents

To cite this article:

Omelyanovskiy VV, Bezdenezhnykh TP, Teptsova TS, Musina NZ. Foreign experience in economic assessment and financing of CAR-T therapy: prospects for Russia. Medical Technologies. Assessment and Choice. 2020;(3):17‑28. (In Russ.)
https://doi.org/10.17116/medtech20204103117

Подписка 2025 (Medical Technologies. Assessment and Choice)
МСФ на ЯМ
Close metadata
Recommended articles:
Cost-effectiveness analysis of low-dose computed tomo­graphy for lung cancer screening. Medi­cal Technologies. Asse­ssment and Choice. 2024;(1):60-73
Cost-effectiveness analysis of HeartMate3 system in patients with severe chro­nic heart failure and redu­ced left ventricular ejection fraction. Medi­cal Technologies. Asse­ssment and Choice. 2024;(2):78-89
Is arti­ficial inte­lligence nece­ssary for healthcare system?. Medi­cal Technologies. Asse­ssment and Choice. 2024;(4):40-48
Cost-effectiveness analysis of deno­sumab therapy in adults with solid tumors and bone meta­stases (in Russian healthcare). Medi­cal Technologies. Asse­ssment and Choice. 2024;(4):74-89
Methods of cost-effectiveness evaluation of endo­vascular patent fora­men ovale closure for seco­ndary prevention of cryptogenic stroke. Russian Journal of Preventive Medi­cine. 2024;(6):105-110
Biotechnological method for bone tissue reco­very: theoretical basis and clinical application. Rege­nerative Biotechnologies, Preventive, Digi­tal and Predictive Medi­cine. 2024;(2):12-17
Biotechnology in deve­lopment of new treatments for osteoarthritis. Rege­nerative Biotechnologies, Preventive, Digi­tal and Predictive Medi­cine. 2024;(2):57-60
Standardized and scalable method for stro­mal-vascular fraction harvesting from adipose tissue. Rege­nerative Biotechnologies, Preventive, Digi­tal and Predictive Medi­cine. 2024;(4):76-81

CAR-T therapy (Chimeric Antigen Receptor T-Cell) resulted in an active discussion of its clinical response in individual anti-tumor immunotherapy. In particular, the first CAR-T drugs approved in the US and Europe, Kimriah and Yescarta, significantly improved overall survival in patients with acute lymphoblastic leukemia and large B-cell lymphoma in the second and subsequent lines of therapy. Despite favorable clinical data on CAR-T technology, there is a formidable economic burden limiting availability of this treatment approach. Potential clinical benefits of CAR-T therapy combined with high cost raise the issue of economic acceptability of these technologies. As healthcare costs rise substantially, the value of advanced therapies is becoming paramount. The purpose of this manuscript is to review foreign experience of economic assessment and financing of CAR-T drugs in the USA, Canada, UK, Netherlands, France, Italy and Spain.

Keywords:

CAR-T
gene therapy
cell therapy
cost-effectiveness analysis
health technology assessment

Authors:

Omelyanovskiy V.V.

Center for Expertise and Quality Control of Medical Care;
Russian Medical Academy of Continuous Professional Education;
Research Financial Institute;
Semashko National Research Institute of Public Health

Bezdenezhnykh T.P.

Center for Expertise and Quality Control of Medical Care;
Financial Research Institute

Teptsova T.S.

Center for Expertise and Quality Control of Medical Care;
I.M. Sechenov First Moscow State Medical University (Sechenov University)

Musina N.Z.

Center for Expertise and Quality Control of Medical Care;
St. Petersburg State Chemical Pharmaceutical University;
Russian Presidential Academy of National Economy and Public Administration

Received:

03.07.2020

Accepted:

17.07.2020

List of references:

  1. Sadelain M, Brentjens R, Rivière I. The basic principles of chimeric antigen receptor design. Cancer Discovery. 2013;3(4):388-398.  https://doi.org/10.1158/2159-8290.CD-12-0548
  2. Gross G, Waks T, Eshhar Z. Generation of effector T cells expressing chimeric T cell receptor with antibody-type specificity. Transplantation Proceedings. 1989;21(1Pt 1):127-130. 
  3. Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity (chimeric genes/antibody variable region). Proceedings of the National Academy of Sciences of the United States of America. 1989;86(24):10024-10028. https://doi.org/10.1073/pnas.86.24.10024
  4. FDA approval brings first gene therapy to the United States. Accessed June 09, 2020. https://www.fda.gov/news-events/press-announcements/fda-approval-brings-first-gene-therapy-united-states
  5. FDA approves CAR-T cell therapy to treat adults with certain types of large B-cell lymphoma. Accessed June 09, 2020. https://www.fda.gov/news-events/press-announcements/fda-approves-car-t-cell-therapy-treat-adults-certain-types-large-b-cell-lymphoma
  6. First two CAR-T cell medicines recommended for approval in the European Union. Accessed June 09, 2020. https://www.ema.europa.eu/en/news/first-two-car-t-cell-medicines-recommended-approval-european-union
  7. Schuster SJ, Bishop MR, Tam CS, Borchmann P, Jaeger U, Waller EK, Holte H, McGuirk J, Jaglowski SM, Tobinai K, Andreadis C, Fleury I, Mielke S, Teshima T, Westin JR, Bachanova V, Foley SR, Ho PJ, Magenau J, Wagner-Johnston ND, Kato K, Kersten MJ, Besien KV, Chu J, Jary A, Anak Ö, Salles G, Maziarz RT. Sustained disease control for adult patients with relapsed or refractory diffuse large B-cell lymphoma: an updated analysis of Juliet, a global pivotal phase 2 trial of tisagenlecleucel. Blood. 2018; 132(Suppl 1):1684-1684. https://doi.org/10.1182/blood-2018-99-115252
  8. Neelapu SS, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, Lin Y, Braunschweig I, Hill BT, Timmerman JM, Deol A, Reagan PM, Stiff PJ, Flinn IW, Farooq U, Goy A, Mcsweeney PA, Muñoz J, Siddiqi T, Chavez JC, Herrera AF, Xue A, Jiang Y, Bot A, Rossi JM, Kim JJ, Go W, Locke FL. 2-Year follow-up and high-risk subset analysis of zuma-1, the pivotal study of axicabtagene ciloleucel (Axi-Cel) in patients with refractory large B cell lymphoma. Biology of Blood and Marrow Transplantation. 2019;25(3):S65.  https://doi.org/10.1016/j.bbmt.2018.12.148
  9. Anderson JK, Mehta A. A review of chimeric antigen receptor T-cells in lymphoma. Expert Review of Hematology. 2019;12(7):551-561.  https://doi.org/10.1080/17474086.2019.1629901
  10. Chimeric Antigen Receptor T-Cell Therapy for B-Cell Cancers: Effectiveness and Value. Final Evidence Report. Prepared for Institute for Clinical and Economic Review, March 23, 2018. Boston, Massachusetts; 2018. Accessed July 28, 2020. https://collections.nlm.nih.gov/catalog/nlm:nlmuid-101744954-pdf
  11. Lin JK, Lerman BJ, Barnes JI, Boursiquot BC, Tan YJ, Robinson A, Davis KL, Owens DK, Goldhaber-Fiebert JD. Cost effectiveness of chimeric antigen receptor T-cell therapy in relapsed or refractory pediatric B-cell acute lymphoblastic leukemia. Journal of Clinical Oncology. 2018;36(32):3192-3202. https://doi.org/10.1200/JCO.2018.79.0642
  12. Sarkar RR, Gloude NJ, Schiff D, Murphy JD. Cost-effectiveness of chimeric antigen receptor T-cell therapy in pediatric relapsed/refractory B-cell acute lymphoblastic leukemia. Journal of the National Cancer Institute. 2019;111(7):1-8.  https://doi.org/10.1093/jnci/djy193
  13. Roth JA, Sullivan SD, Lin VW, Bansal A, Purdum AG, Navale L, Cheng P, Ramsey SD. Cost-effectiveness of axicabtagene ciloleucel for adult patients with relapsed or refractory large B-cell lymphoma in the United States. Journal of Medical Economics. 2018; 21(12):1238-1245. https://doi.org/10.1080/13696998.2018.1529674
  14. CADTH. Tisagenlecleucel for Acute Lymphoblastic Leukemia and Diffuse Large B-Cell Lymphoma. CADTH Summarizing the Evidence. January 2019. Accessed June 09, 2020. https://cadth.ca/sites/default/files/pdf/car-t/ct0001-op0538-in-brief-e-jan2019.pdf
  15. Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Recommendations CADTH.ca [Electronic resource]. Accessed June 09, 2020. https://www.cadth.ca/axicabtagene-ciloleucel-large-b-cell-lymphoma-recommendations
  16. Tisagenlecleucel-T (Kymriah) for the treatment of ALL. Report. National Health Care Institute [Electronic resource]. Accessed June 09, 2020. https://english.zorginstituutnederland.nl/publications/reports/2018/12/18/tisagenlecleucel-t-kymriah-for-the-treatment-of-all
  17. Tisagenlecleucel (Kymriah) for the treatment of DLBCL. Report. National Health Care Institute [Electronic resource]. Accessed June 09, 2020. https://english.zorginstituutnederland.nl/publications/reports/2019/03/07/tisagenlecleucel-kymriah-for-the-treatment-of-dlbcl
  18. Axicabtagene ciloleucel (Yescarta) for the treatment of adult patients with recurring or refractory diffuse large-cell B-cell lymphoma (DLBCL) and primary mediastinal large-cell B-cell lymphoma (PMBCL). Report. National Health Care Institute [Electronic resource]. Accessed June 09, 2020. https://english.zorginstituutnederland.nl/publications/reports/2019/03/07/axicabtagene-ciloleucel-yescarta
  19. NICE. Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years [Electronic resource]. 2018. Accessed June 09, 2020. https://www.nice.org.uk/guidance/ta554/resources/tisagenlecleucel-for-treating-relapsed-or-refractory-bcell-acute-lymphoblastic-leukaemia-in-people-aged-up-to-25-years-pdf-82607021872837
  20. Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies [Electronic resource]. 2019. Accessed July 28, 2020. https://www.nice.org.uk/guidance/ta567
  21. NICE. Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma after 2 or more systemic therapies [Electronic resource]. 2019. Accessed July 28, 2020. https://www.nice.org.uk/guidance/ta559/resources/axicabtagene-ciloleucel-for-treating-diffuse-large-bcell-lymphoma-and-primary-mediastinal-large-bcell-lymphoma-after-2-or-more-systemic-therapies-pdf-82607030270917
  22. Cancer Drugs Fund Managed Access Agreement Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma after 2 or more systemic therapies [ID1115] [Electronic resource]. Accessed July 28, 2020. https://www.nice.org.uk/guidance/ta559/documents/final-appraisal-determination-document-3
  23. Novartis receives first ever FDA approval for a CAR-T cell therapy, Kymriah(TM) (CTL019), for children and young adults with B-cell ALL that is refractory or has relapsed at least twice [Electronic resource]. https://www.novartis.com/news/media-releases/novartis-receives-first-ever-fda-approval-car-t-cell-therapy-kymriahtm-ctl019-children-and-young-adults-b-cell-all-refractory-or-has-relapsed-least-twice Accessed July 28, 2020.
  24. The Medicare Payment Advisory Commission. Medicare Part B drug payment policy issues [Electronic resource]. 2019. Accessed July 28, 2020. https://medpac.gov/docs/default-source/reports/jun17_ch2.pdf
  25. Castillo E, Jensen TS. UnitedHealthcare. Re: Formal Request for National Coverage Determination for Chimeric Antigen Receptor T-Cell Therapies [Electronic resource]. 2018. Accessed July 28, 2020. https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologlcDrugsAdvisoryCommittee/ucmS66165.htm
  26. The Centers for Medicare & Medicaid Services. Decision Memo for Chimeric Antigen Receptor (CAR) T-cell Therapy for Cancers (CAG-00451N [Electronic resource]. 2019. Accessed July 28, 2020. https://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=291
  27. Medicare to pay hundreds of thousands for CAR-T therapies [Electronic resource]. 2018. Accessed July 28, 2020. https://www.biopharmadive.com/news/medicare-to-pay-hundreds-of-thousands-for-car-t-therapies/520806
  28. New Medical Services and New Technologies [Electronic resource]. Accessed July 28, 2020  https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/newtech
  29. Fiscal Year (FY) 2020 Medicare Hospital Inpatient Prospective Payment System (IPPS) and Long Term Acute Care Hospital (LTCH) Prospective Payment System (CMS-1716-F). CMS [Electronic resource]. Accessed July 28, 2020. https://www.cms.gov/newsroom/fact-sheets/fiscal-year-fy-2020-medicare-hospital-inpatient-prospective-payment-system-ipps-and-long-term-acute-0
  30. AIFA announces funding of CAR-T cell therapy using new reimbursement approach [Electronic resource]. 2019. Accessed July 28, 2020. https://mapbiopharma.com/home/2019/08/aifa-announces-funding-of-car-t-cell-therapy-using-new-reimbursement-approach
  31. Le terapie geniche CAR-T [Electronic resource]. Accessed July 28, 2020. https://www.ema.europa.eu/en/documents/assessment-report/kymriah-epar-public
  32. CAR-T: farmaco di Novartis innovativo anche nel modello di pagamento [Electronic resource]. 2019. Accessed July 28, 2020. https://www.osservatorioterapieavanzate.it/regolatorio/car-t-farmaco-di-novartis-innovativo-anche-nel-modello-di-pagamento Accessed July 28, 2020.
  33. CAR T-Cell Therapies In The EU5 What Can We Expect From Payers. Accessed June 09, 2020. https://www.cellandgene.com/doc/car-t-cell-therapies-in-the-eu-what-can-we-expect-from-payers-0001
  34. ATU — Autorisations temporaires d’utilisation — Ministère des Solidarités et de la Santé [Electronic resource]. Accessed June 09, 2020. https://solidarites-sante.gouv.fr/ministere/acteurs/instances-rattachees/article/atu-autorisations-temporaires-d-utilisation
  35. HAS-Direction de l’Evaluation Médicale, Economique et de Santé Publique COMMISSION DE LA TRANSPARENCE [Electronic resource]. Accessed June 09, 2020. https://www.has-sante.fr/upload/docs/application/pdf/2018-12/yescarta_pic_ins_avis3_ct17214.pdf
  36. HAS-Direction de l’Evaluation Médicale, Economique et de Santé Publique COMMISSION DE LA TRANSPARENCE [Electronic resource]. Accessed June 09, 2020. https://www.has-sante.fr/upload/docs/evamed/CT-16972_LAMZEDE_PIC_INS_Avis3_CT16972.pdf
  37. Arrêté du 8 juillet 2019 modifiant la liste des spécialités pharmaceutiques prises en charge en sus des prestations d’hospitalisation mentionnée à l’article L 162-22-7 du code de la sécurité sociale. Legifrance [Electronic resource]. Accessed June 09, 2020. https://www.legifrance.gouv.fr/affichTexte.do?cidTexte=JORFTEXT000038757767&categorieLien=id
  38. De SANIDAD. SECRETARÍA GENERAL DE SANIDAD Y CONSUMO MINISTERIO DIRECCIÓN GENERAL DE CARTERA BÁSICA DE SALUD. Preguntas y respuestas frecuentes sobre el sistema de información para determinar el valor terapéutico en la práctica clínica real de los medicamentos de alto impacto sanitario y económico en el sistema nacional de salud (Valtermed). [Electronic resource]. Accessed June 09, 2020. https://www.mscbs.gob.es/profesionales/farmacia/valtermed/docs/VALTERMED_Preguntas_y_Respuestas.pdf
  39. Los protocolos farmacoclínicos de los CART estrenarán el uso de Valtermed. @diariofarma [Electronic resource]. Accessed June 09, 2020. https://www.diariofarma.com/2019/07/07/los-protocolos-farmacoclinicos-de-los-cart-estrenaran-el-uso-de-valtermed
  40. Jørgensen J, Hanna E, Kefalas P. Outcomes-based reimbursement for gene therapies in practice: the experience of recently launched CAR-T cell therapies in major European countries. Journal of Market Access & Health Policy. 2020;8(1):1715536. https://doi.org/10.1080/20016689.2020.1715536
  41. Whittington MD, Ollendorf DA, Campbell JD. Accounting for All Costs in the Total Cost of Chimeric Antigen Receptor T-Cell Immunotherapy. JAMA Oncology. 2018;4(12):1784-1785. https://doi.org/10.1001/jamaoncol.2018.4625
  42. Hernandez I, Prasad V, Gellad WF. Accounting for All Costs in the Total Cost of Chimeric Antigen Receptor T-Cell Immunotherapy-Reply. JAMA Oncology. 2018;4(12):1785-1786. https://doi.org/10.1001/jamaoncol.2018.4657

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.